IPP Bureau
Orchid Pharma reports positive EBIDTA in Q2
By IPP Bureau - November 15, 2022
The company is focussed on increasing the capacity utilizations while controlling costs
Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
By IPP Bureau - November 15, 2022
The company sees the business reaching $100mn
Nikon India forays into the Indian healthcare sector
By IPP Bureau - November 15, 2022
Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot
Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP
By IPP Bureau - November 15, 2022
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
By IPP Bureau - November 14, 2022
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
GL Chemtech appoints Dr. John Warner as Green Chemistry Innovation Advisor
By IPP Bureau - November 14, 2022
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
By IPP Bureau - November 14, 2022
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr
By IPP Bureau - November 14, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
Biocon Biologics features on ASIA IP ELITE List 2022
By IPP Bureau - November 14, 2022
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
GSK India announces 9% sales growth across General Medicines and Specialty business
By IPP Bureau - November 14, 2022
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Aurobindo Pharma Q2 FY23 revenue down 3.4%
By IPP Bureau - November 14, 2022
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Alembic receives USFDA final approval for Cyclophosphamide Capsules
By IPP Bureau - November 14, 2022
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Sanofi, GSK’s next-generation COVID-19 booster vaccine approved by the European Commission
By IPP Bureau - November 11, 2022
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr
By IPP Bureau - November 11, 2022
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster
By IPP Bureau - November 11, 2022
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
